

Primetime received an SBIR Fast-Track grant award to develop a novel treatment for parasitic disease

October 05, 2022

Primetime Life Sciences, LLC is a pharmaceutical company focused on discovering and developing new and smart treatments using a multi-disciplinary and highly collaborative translational medicine approach. It announced it had been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH) for an innovative treatment to combat giardiasis with a novel mechanism of action. Giardia Lamblia is a highly infectious waterborne parasite that causes severe diarrhea.

The Fast Track SBIR grant award consists of two phases. An initial Phase I award of \$300,000 is granted in the near term. Upon meeting the Phase I milestones, Phase II of the project would support pre-clinical studies toward IND submission of our lead compound. Together, the Fast-Track SBIR grant has the potential to provide a total of approximately \$2.9 million in nondilutive financial resources.

“Fast Track SBIR grant award is highly competitive, and receiving the award validates our approach to develop an innovative treatment for giardiasis,” said Dr. Janak Padia, President and CEO of Primetime Life Sciences. “Current anti-giardiasis drugs have undesirable side effects, and they fail to cure giardiasis in about 20% of cases. Our treatment will provide a safe and effective treatment for giardiasis”.

NOTES TO EDITORS

About Primetime Life Sciences, LLC

Primetime Life Sciences (www.primetimelifesci.com) is a Maryland-based discovery and development company focusing on small molecule drugs. Our mission is to expedite the discovery and development of new and smart treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. The Company has developed a mutual prodrug platform using "Metformin Linker Kit" to improve pharmacokinetic and safety profiles of known drugs. The Company pipeline includes CNS, cancer, and parasitic therapeutics. For more information, please contact Dr. Janak Padia at jpadia@primetimelifesci.com